Biotech News

CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer

CG Oncology, Inc. (CGON)CG Oncology, Inc.Commercial

CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than 20 years of commercial leadership experience, Ms. Kalofonos will lead the Company's commercial strategy and execution as CG Oncology advances toward the potential launch of cretostimogene grenadenorepvec and continues to establish itself as a leader in bladder cancer.

Related news

CG Oncology, Inc.

Bladder-Cancer Immunotherapy CG Oncology develops oncolytic immunotherapies for bladder cancer. Its lead candidate is administered directly into the bladder to selectively replicate in tumor cells and stimulate an antitumor immune response. Cretostimogene Grenadenorepvec Cretostimogene has been studied across more than 600 patients with...

Recent company news

Stock data

Close
81.90 USD
Market cap
4.9B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States